Crypto Rebound, Biotech Wins as AI Stocks Stall

Opening Recap

Market Pulse: Crypto gears up after funding rates plunged to 2020 depths on Binance, while biotech flickers back to life with fresh FDA nods and tech stocks pause under AI pressure.

Key Movers: Argenx’s FDA win in myasthenia gravis sparks sector hope; Cloudflare’s slower growth rattles infrastructure bulls; semaglutide compounding ban talk rattles pharma supply chains.

Macro & Politics: A proposed FDA ban on bulk compounding of semaglutide and tirzepatide underlines regulators’ muscle, spotlighting the power of policy in market swings.

What’s Next: Watch Micron’s next earnings signal for a live read on chip demand and potential merger whispers.

Market Commentary

What everyone’s missing: the proposed ban on bulk compounding of semaglutide and tirzepatide is a latent threat to thousands of patients and bulls blindly chasing biotech catalysts. While argenx’s new approval headline stole the spotlight, the deeper risk is supply-chain constraints ushering in unforeseen volatility.

Here’s a twist: Cloudflare’s AI growth stumble and Bitcoin’s brewing short squeeze are two sides of the same capital-rotation coin. As tech bulls recalibrate on rising costs, nervous money can pivot into crypto—so a dip in one arena may ignite a surge in the other.

Action takeaway: position for cross-asset swings—trim exposure in overstretched AI infrastructure and allocate a sliver to crypto’s squeeze setup. Markets move in unexpected arcs; lean into the under-the-radar stories driving tomorrow’s returns.